KPIs & Operating Metrics(New)
Assets By SegmentBreakdown Of AssetsCapital Expenditure By SegmentCost Of Goods And Services SoldDeferred IncomeDepreciation And Amortization By SegmentEmployee StatisticsGross Margin %Gross Margin By Segment %Gross Margin By Segment Annual %Gross ProfitGross Profit By SegmentGross Profit By Segment AnnualIncome Before Income TaxLong Lived Assets By GeographyNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Lease LiabilitiesOperating Margin By Segment %Operating Profit By SegmentOpex As A % Of Total Revenue %OPEX SegregationProperty, Plant And Equipment, Net BreakdownRevenue By Country AnnualRevenue By Country Annual %Revenue By GeographyRevenue By Geography %Revenue By Geography AnnualRevenue By Geography Annual %Revenue By Market GroupRevenue By Market Group %Revenue By Market Group AnnualRevenue By Market Group Annual %Revenue By Product CategoryRevenue By Product Category %Revenue By Product Category AnnualRevenue By Product Category Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

West Pharmaceutical Services (WST) Gross Profit (2009 - 2026)

West Pharmaceutical Services recorded quarterly Gross Profit of $296.4 million in Q1 2026, down 2.47% quarter-over-quarter from $303.9 million in Q4 2025, and up 27.81% year-over-year from $231.9 million in Q1 2025.

West Pharmaceutical Services' Gross Profit history runs 18 years deep, the most recent figure standing at $296.4 million for Q1 2026.

  • In Q1 2026, Gross Profit rose 27.81% year-over-year to $296.4 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 16.83% YoY), while the FY2025 annual figure was $1.1 billion, up 10.57% from the prior year.
  • Gross Profit came in at $296.4 million for Q1 2026 at West Pharmaceutical Services, down from $303.9 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $321.5 million in Q2 2022 to a low of $230.0 million in Q2 2024.
  • A 5-year average of $274.4 million and a median of $273.9 million in 2025 frame the typical range for Gross Profit.
  • Across the five-year window, Gross Profit declined 21.07% in 2024 and increased 27.81% in 2026, its largest moves.
  • West Pharmaceutical Services' Gross Profit stood at $262.1 million in 2022, then climbed by 6.14% to $278.2 million in 2023, then declined by 1.65% to $273.6 million in 2024, then advanced by 11.07% to $303.9 million in 2025, then fell by 2.47% to $296.4 million in 2026.
  • According to Business Quant data, Gross Profit over the past three periods registered $296.4 million, $303.9 million, and $294.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.